Fig. 1

RECIST response and time on study A. Waterfall plot indicating best response and best percent change in tumor size for all patients eligible for response evaluation ( n = 13). Dose level (DL) is indicated as in the legend and the dotted line at 20% indicates the threshold for stable disease (SD) according to RECIST v1.1 criteria. Two patients (represented by *) showed new liver lesions at the restaging performed at the end of cycle 2 and were considered as progressive disease according to RECIST v1.1 criteria. One patient (represented by &), although did not show more than 20% increase in the target lesions, was deemed to have clinical progressive disease due to worsening pain, bloating, and ascites recorded at the clinical visit after restaging performed at the end of cycle 2. B. Spider plot of percent change in tumor size across all cycles. Each cycle is 28 days in length (4 weeks). Among patients with SD, three patients were restaged after cycle 2. One patient was restaged multiple times after cycle 2 until the end of cycle 9 (36 weeks of treatment) C. Swimmer plot of time on study by dose level for all evaluable patients. All 4 patients with SD after at least 4 doses of NEO-201 (8 weeks of treatment) elected to continue receiving therapy